$60 degrees pharmaceuticals, I-To The Moon - Tiger Brokers Online Investing Community - To The Moon

$60 degrees pharmaceuticals, Inc.(SXTP)$ 💎 **Seize the Next Wave of Biotech Boom! SXTP: An Investment Opportunity You Can't Miss!**

60 Degrees Pharmaceuticals (NASDAQ: SXTP) has officially submitted a Breakthrough Therapy Designation request to the FDA for its core drug, Tafenoquine, for **babesiosis**. This is not only a milestone for the company, but also a potential super catalyst to ignite its stock price!

🌱 **Huge Market, Zero Competition!** Babesiosis is a dangerous tick-borne parasitic disease for which there is currently **no specific FDA-approved treatment** in the United States. The company estimates that there are **4,400 to 190,000 unmet medical needs** annually. Independent research indicates that the U.S. babesiosis market has a **peak annual sales potential of $245 million**, with cumulative revenue potential reaching **approximately $1.1 billion** by patent expiration in 2035. This is a completely untapped blue ocean market!

🚀 **Impressive Clinical Data, Clear Regulatory Path!** **The first patient treated with the drug tested negative after completing the course of treatment using the FDA-approved, highest-sensitivity detection method—no Babesia infection was detected!** The company plans to hold a Type B meeting with the FDA in early 2026 to discuss the requirements for a Supplemental New Drug Application (sNDA), paving the way for final market approval.

🎯 **Analysts are bullish, with significant upside potential!** Ascendiant Capital Markets has given SXTP a "Buy" rating with a target price of $3. At the current share price, the potential upside is extremely attractive!

💡 **Investment Highlights:**

* **Target Company**: 60 Degrees Pharmaceuticals (NASDAQ: SXTP)

* **Core Catalyst**: FDA Breakthrough Therapy Designation for Tafenoquine for the treatment of Babesia disease (application submitted, decision pending)

* **Key Milestones**: FDA Type B meeting in early 2026, and subsequent sNDA submission.

* **Market Potential:** Up to **US$1.1 billion** in cumulative revenue potential.

**Opportunity is at your fingertips; don't miss this burgeoning biotech stock!**

💰Stocks to watch today?(27 Feb）

1. What news/movements are worth noting in the market today? Any stocks to watch? 2. What trading opportunities are there? Do you have any plans? 🎁 Make a post here, everyone stands a chance to win Tiger coins!

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

1

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":504411178774960,"tweetId":"504411178774960","gmtCreate":1764174475233,"gmtModify":1764174587140,"author":{"id":4188648172846562,"idStr":"4188648172846562","authorId":4188648172846562,"authorIdStr":"4188648172846562","name":"晴天无锋","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3,"starInvestorFlag":false},"themes":[{"themeId":"470d3ab575ca43caaed8156645b7ccbe","categoryId":"ab3d937a5fd848c08008411a9be702b5","name":"💰Stocks to watch today?(27 Feb）","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":470d3ab575ca43caaed8156645b7ccbe}&rnconfig={\"headerBarHidden\": true}","description":"1. What news/movements are worth noting in the market today? Any stocks to watch? \n2. What trading opportunities are there? Do you have any plans?\n🎁 Make a post here, everyone stands a chance to win Tiger coins!","image":"https://static.tigerbbs.com/cd8eaff2e99964ab7a80d92cc196fcd3"}],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><p><a href=\"https://ttm.financial/S/SXTP\">$60 degrees pharmaceuticals, Inc.(SXTP)$ </a> 💎 **Seize the Next Wave of Biotech Boom! SXTP: An Investment Opportunity You Can't Miss!**</p>\n<p><br></p>\n<p>60 Degrees Pharmaceuticals (NASDAQ: SXTP) has officially submitted a Breakthrough Therapy Designation request to the FDA for its core drug, Tafenoquine, for **babesiosis**. This is not only a milestone for the company, but also a potential super catalyst to ignite its stock price!</p>\n<p><br></p>\n<p>🌱 **Huge Market, Zero Competition!** Babesiosis is a dangerous tick-borne parasitic disease for which there is currently **no specific FDA-approved treatment** in the United States. The company estimates that there are **4,400 to 190,000 unmet medical needs** annually. Independent research indicates that the U.S. babesiosis market has a **peak annual sales potential of $245 million**, with cumulative revenue potential reaching **approximately $1.1 billion** by patent expiration in 2035. This is a completely untapped blue ocean market!</p>\n<p><br></p>\n<p>🚀 **Impressive Clinical Data, Clear Regulatory Path!** **The first patient treated with the drug tested negative after completing the course of treatment using the FDA-approved, highest-sensitivity detection method—no Babesia infection was detected!** The company plans to hold a Type B meeting with the FDA in early 2026 to discuss the requirements for a Supplemental New Drug Application (sNDA), paving the way for final market approval.</p>\n<p><br></p>\n<p>🎯 **Analysts are bullish, with significant upside potential!** Ascendiant Capital Markets has given SXTP a \"Buy\" rating with a target price of $3. At the current share price, the potential upside is extremely attractive!</p>\n<p><br></p>\n<p>💡 **Investment Highlights:**</p>\n<p><br></p>\n<p>* **Target Company**: 60 Degrees Pharmaceuticals (NASDAQ: SXTP)</p>\n<p><br></p>\n<p>* **Core Catalyst**: FDA Breakthrough Therapy Designation for Tafenoquine for the treatment of Babesia disease (application submitted, decision pending)</p>\n<p><br></p>\n<p>* **Key Milestones**: FDA Type B meeting in early 2026, and subsequent sNDA submission.</p>\n<p><br></p>\n<p>&nbsp;* **Market Potential:** Up to **US$1.1 billion** in cumulative revenue potential.</p>\n<p><br></p>\n<p>**Opportunity is at your fingertips; don't miss this burgeoning biotech stock!**</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://ttm.financial/S/SXTP\">$60 degrees pharmaceuticals, Inc.(SXTP)$ </a> 💎 **Seize the Next Wave of Biotech Boom! SXTP: An Investment Opportunity You Can't Miss!**</p>\n<p><br></p>\n<p>60 Degrees Pharmaceuticals (NASDAQ: SXTP) has officially submitted a Breakthrough Therapy Designation request to the FDA for its core drug, Tafenoquine, for **babesiosis**. This is not only a milestone for the company, but also a potential super catalyst to ignite its stock price!</p>\n<p><br></p>\n<p>🌱 **Huge Market, Zero Competition!** Babesiosis is a dangerous tick-borne parasitic disease for which there is currently **no specific FDA-approved treatment** in the United States. The company estimates that there are **4,400 to 190,000 unmet medical needs** annually. Independent research indicates that the U.S. babesiosis market has a **peak annual sales potential of $245 million**, with cumulative revenue potential reaching **approximately $1.1 billion** by patent expiration in 2035. This is a completely untapped blue ocean market!</p>\n<p><br></p>\n<p>🚀 **Impressive Clinical Data, Clear Regulatory Path!** **The first patient treated with the drug tested negative after completing the course of treatment using the FDA-approved, highest-sensitivity detection method—no Babesia infection was detected!** The company plans to hold a Type B meeting with the FDA in early 2026 to discuss the requirements for a Supplemental New Drug Application (sNDA), paving the way for final market approval.</p>\n<p><br></p>\n<p>🎯 **Analysts are bullish, with significant upside potential!** Ascendiant Capital Markets has given SXTP a \"Buy\" rating with a target price of $3. At the current share price, the potential upside is extremely attractive!</p>\n<p><br></p>\n<p>💡 **Investment Highlights:**</p>\n<p><br></p>\n<p>* **Target Company**: 60 Degrees Pharmaceuticals (NASDAQ: SXTP)</p>\n<p><br></p>\n<p>* **Core Catalyst**: FDA Breakthrough Therapy Designation for Tafenoquine for the treatment of Babesia disease (application submitted, decision pending)</p>\n<p><br></p>\n<p>* **Key Milestones**: FDA Type B meeting in early 2026, and subsequent sNDA submission.</p>\n<p><br></p>\n<p>&nbsp;* **Market Potential:** Up to **US$1.1 billion** in cumulative revenue potential.</p>\n<p><br></p>\n<p>**Opportunity is at your fingertips; don't miss this burgeoning biotech stock!**</p></body></html>","text":"$60 degrees pharmaceuticals, Inc.(SXTP)$ 💎 **Seize the Next Wave of Biotech Boom! SXTP: An Investment Opportunity You Can't Miss!** 60 Degrees Pharmaceuticals (NASDAQ: SXTP) has officially submitted a Breakthrough Therapy Designation request to the FDA for its core drug, Tafenoquine, for **babesiosis**. This is not only a milestone for the company, but also a potential super catalyst to ignite its stock price! 🌱 **Huge Market, Zero Competition!** Babesiosis is a dangerous tick-borne parasitic disease for which there is currently **no specific FDA-approved treatment** in the United States. The company estimates that there are **4,400 to 190,000 unmet medical needs** annually. Independent research indicates that the U.S. babesiosis market has a **peak annual sales potential of $245 million**, with cumulative revenue potential reaching **approximately $1.1 billion** by patent expiration in 2035. This is a completely untapped blue ocean market! 🚀 **Impressive Clinical Data, Clear Regulatory Path!** **The first patient treated with the drug tested negative after completing the course of treatment using the FDA-approved, highest-sensitivity detection method—no Babesia infection was detected!** The company plans to hold a Type B meeting with the FDA in early 2026 to discuss the requirements for a Supplemental New Drug Application (sNDA), paving the way for final market approval. 🎯 **Analysts are bullish, with significant upside potential!** Ascendiant Capital Markets has given SXTP a \"Buy\" rating with a target price of $3. At the current share price, the potential upside is extremely attractive! 💡 **Investment Highlights:** * **Target Company**: 60 Degrees Pharmaceuticals (NASDAQ: SXTP) * **Core Catalyst**: FDA Breakthrough Therapy Designation for Tafenoquine for the treatment of Babesia disease (application submitted, decision pending) * **Key Milestones**: FDA Type B meeting in early 2026, and subsequent sNDA submission. * **Market Potential:** Up to **US$1.1 billion** in cumulative revenue potential. **Opportunity is at your fingertips; don't miss this burgeoning biotech stock!**","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/504411178774960","repostId":0,"isVote":1,"tweetType":1,"viewCount":803,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["SXTP"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":1815,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/504411178774960"}